Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis

被引：24

作者：

Stacey L. Berg

Marc C. Chamberlain

机构：

[1] Department of Neurology, University of Southern California, Norris Compreh. Cancer Ctr./Hospital, Los angeles, CA 90033-0804

来源：

Current Oncology Reports | 2003年 / 5卷 / 1期

关键词：

Cytarabine; Topotecan; Leptomeningeal Metastasis; Thiotepa; Central Nervous System Relapse;

D O I：

10.1007/s11912-003-0084-9

中图分类号：

学科分类号：

摘要：

Metastasis to the leptomeninges occurs in many common cancers, including leukemia; lung, breast, and gastrointestinal cancers; and tumors of the brain. By way of the flow of cerebrospinal fluid, leptomeningeal metastasis spreads throughout the neuraxis. Consequently, therapy for leptomeningeal metastasis must be directed to the entire central nervous system (CNS). Treatment often consists of involved-field radiotherapy, systemic chemotherapy, and intrathecal chemotherapy. However, because meningeal spread occurs most often in advanced disease, treatment is mainly palliative, except in childhood leukemia, where durable remission has been reported. This article outlines the role of systemic and intrathecal chemotherapy in patients with leptomeningeal metastases. Strategies for symptom management in these patients are also described. Copyright © 2003 by Current Science Inc.

引用

页码：29 / 40

页数：11

共 120 条

[51]

Adamson P., Zimm S., Ragab A., Et al., A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors, Cancer Chemother. Pharmacol., 26, pp. 343-344, (1990)

[52]

Blaney S., Cole D., Balis E., Et al., Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates, Cancer Res., 53, pp. 725-727, (1993)

[53]

Blaney S.M., Phillips P.C., Packer R.J., Et al., Phase II evaluation of topotecan for pediatric central nervous system tumors, Cancer, 78, pp. 527-531, (1996)

[54]

Friedman H.S., Kerby T., Fields S., Et al., Topotecan treatment of adults with primary malignant glioma, Cancer, 85, pp. 1160-1165, (1999)

[55]

Macdonald D., Cairncross G., Stewart D., Et al., Phase II study of Topotecan in patients with recurrent malignant glioma, Ann. Oncol., 7, pp. 205-207, (1996)

[56]

Oberhoff C., Kieback D.G., Wurstlein R., Et al., Topotecan chemotherapy in patients with breast cancer and brain metastases: Results of a pilot study, Onkologie, 24, pp. 256-260, (2001)

[57]

Blaney S.M., Takimoto C., Murry D.J., Et al., Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates, Cancer Chemother. Pharmacol., 41, pp. 464-468, (1998)

[58]

Friedman H.S., Petros W.P., Friedman A.H., Et al., Irinotecan therapy in adults with recurrent or progressive malignant glioma, J. Clin. Oncol., 17, pp. 1516-1525, (1999)

[59]

Chamberlain M.C., Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme, J. Neuroncol., 56, pp. 183-188, (2002)

[60]

Chamberlain M.C., Salvage chemotherapy with CPT-11 for oligodendroglioma, J. Neurooncol., 59, pp. 157-163, (2002)

← 1 2 3 4 5 6 7 8 9 10 →